Protective effect of single-dose adjuvanted pandemic influenza vaccine in children.

Influenza and Other Respiratory Viruses
P G Van BuynderF-W Tremblay

Abstract

During the first wave of A/California/7/2009(H1N1) influenza, high rates of hospitalization in children under 5 years were seen in many countries. Subsequent policies for vaccinating children varied in both type of vaccine and number of doses. In Canada, children 36 months to <10 years received a single dose of 0.25 ml of the GSK adjuvanted vaccine (Arepanrix) equivalent to 1.9 microg HA. Children 6 months to 35 months received two doses as did those 36-119 months with chronic medical conditions. We conducted a community-based case-control vaccine effectiveness (VE) review of children under 10 years with influenza like illness who were tested for H1N1 infection at the central provincial laboratory. Laboratory-confirmed influenza was the primary outcome, and vaccination status the primary exposure to assess VE after a single 0.25-ml dose. If vaccination was designated to be effective after 14 days, no vaccinated child had laboratory-confirmed influenza compared to 38% of controls. The VE of 100% was statistically significant for children <10 years of age and <5 years considered separately. If vaccination was considered effective after 10 days, VE dropped to 96% overall but was statistically significant and over 90% in all age su...Continue Reading

References

Aug 1, 1993·International Journal of Epidemiology·C P Farrington
Jan 27, 2006·The Cochrane Database of Systematic Reviews·S SmithA Rivetti
Oct 17, 2006·American Family Physician·Steven E Roskos
Apr 4, 2007·International Journal of Epidemiology·Evan W OrensteinWalter A Orenstein
Nov 4, 2009·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·UNKNOWN New South Wales public health network
Nov 4, 2009·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Mg BakerN Wilson
Mar 11, 2010·JAMA : the Journal of the American Medical Association·Mark LoebStephen D Walter

❮ Previous
Next ❯

Citations

Apr 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ake OrtqvistBo Svenungsson
Jan 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Woolf T WalkerAndrew J Pollard
Aug 2, 2012·The Journal of Infectious Diseases·Amra UzicaninUNKNOWN Maine 2009 Influenza A (H1N1) Vaccine Effectiveness Evaluation Group
Mar 21, 2012·BMC Infectious Diseases·Bernardo Rafael Guzmán HerradorKatrine Borgen
Jul 19, 2011·Emerging Infectious Diseases·James E FieldingHeath A Kelly
Nov 26, 2010·Expert Review of Vaccines·Woolf T Walker, Saul N Faust
Jul 28, 2013·Expert Review of Vaccines·Christopher B Fox, Jean Haensler
Oct 29, 2014·Expert Review of Vaccines·Sheena G SullivanBenjamin J Cowling
Apr 5, 2012·Vaccine·S Jiménez-JorgeUNKNOWN Spanish Influenza Sentinel Surveillance System
Apr 14, 2012·Influenza and Other Respiratory Viruses·Paul G Van BuynderBao Gang Fei
Apr 15, 2015·Vaccine·Åke ÖrtqvistMargareta Eriksson
Apr 24, 2010·International Journal for Parasitology·Deborah C HoltJonathan R Carapetis
Sep 17, 2016·Human Vaccines & Immunotherapeutics·Nathalie Garçon, Alberta Di Pasquale
Mar 18, 2017·Vaccine·Louise E LansburyJonathan S Nguyen-Van-Tam
Nov 23, 2016·World Journal of Clinical Pediatrics·Olivier Fléchelles The Pediatric Canadian Critical Care Trials Group H N Collaborative And Groupe Francophone de Réanimation Et Urgences Pédiat
Jan 13, 2018·Frontiers in Immunology·Amanda L WilkinsAndrew J Pollard
Aug 17, 2012·The Cochrane Database of Systematic Reviews·Tom JeffersonEliana Ferroni
Feb 2, 2018·The Cochrane Database of Systematic Reviews·Tom JeffersonVittorio Demicheli
Jan 11, 2014·Human Vaccines & Immunotherapeutics·Prasad S KulkarniSomnath Mangrule

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SAS

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.